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Background: Life-style (LI) or pharmacological intervention is effective for prevention of early stage diabetes mellitus (DM), which is characterized 
as postprandial hyperglycemia (PPG). However, it remains unknown whether these interventions may prevent the progression of coronary artery 
diseases (CAD).
Methods: The DIANA study is a prospective randomized open-label multi-center trial. A total of 302 patients with both CAD and impaired glucose 
tolerance (IGT) or DM and HbA1c<6.5% were randomly assigned to LI (n=101), Voglibose (n=100) or Nateglinide (n=101). Quantitative coronary 
angiography (QCA) and 75g-OGTT were reevaluated one-year after randomization. Diameters of middle section in each major coronary segment were 
averaged to determine vessel diameter. We defined segments of a diameter<1.5mm as diseased lesions, and determined total and averaged lesion 
length.
Results: Voglibose increased the number of normal glucose tolerance, while Nateglinide reduced HbA1c level. Other metabolic profiles including 
PPG, HbA1c, insulin sensitivity and adiponectin were changed similarly at one year. The significant progression of coronary atherosclerosis could 
not be observed in LI group and this efficacy was comparable with other two groups (Table). The incidence of adverse events was similar between 
Voglibose and Nateglinide groups.
Conclusions: In Japanese early stage diabetic patients with CAD, LI had favorable impacts on coronary atherosclerosis equivalent to 
pharmacological therapies.
